Loading...

Advicenne S.A.

ALDVI.PAEURONEXT
Healthcare
Biotechnology
1.76
0.01(0.57%)

Advicenne S.A. ALDVI.PA Peers

See (ALDVI.PA) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ALDVI.PA€1.76+0.57%21.6M-3.67-€0.48N/A
UCB.BR€157.65+1.61%30B28.77€5.48+0.88%
ARGX.BR€473.20+0.08%28.9B33.37€14.18N/A
TUB.BR€126.00+0.80%5.6B62.38€2.02+0.83%
GLPG.AS€23.96-2.20%1.6B-8.78-€2.73N/A
GTBP.PA€280.50N/A626.7M-4.10-€68.39N/A
PHARM.AS€0.91-3.15%617.7M-45.40-€0.02N/A
MEDCL.PA€16.57+0.67%547.9M-15.20-€1.09N/A
VLA.PA€2.36-2.96%401.4M-4.21-€0.56N/A
IVA.PA€2.85-0.87%396.5M-0.93-€3.08N/A
Showing 1 to 10 of 69 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ALDVI.PA vs UCB.BR Comparison

ALDVI.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALDVI.PA stands at 21.6M. In comparison, UCB.BR has a market cap of 30B. Regarding current trading prices, ALDVI.PA is priced at €1.76, while UCB.BR trades at €157.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALDVI.PA currently has a P/E ratio of -3.67, whereas UCB.BR's P/E ratio is 28.77. In terms of profitability, ALDVI.PA's ROE is +0.44%, compared to UCB.BR's ROE of +0.11%. Regarding short-term risk, ALDVI.PA is less volatile compared to UCB.BR. This indicates potentially lower risk in terms of short-term price fluctuations for ALDVI.PA.

Stock Price Comparison

Loading...

Frequently Asked Questions

;